Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating) CMO Joakim Wijkstrom sold 7,720 shares of the firm’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $6.23, for a total value of $48,095.60. Following the completion of the transaction, the chief marketing officer now directly owns 121,653 shares in the company, valued at approximately $757,898.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Vanda Pharmaceuticals Stock Performance
Shares of VNDA stock opened at $6.33 on Tuesday. Vanda Pharmaceuticals Inc. has a 52-week low of $6.18 and a 52-week high of $12.34. The firm has a market capitalization of $359.42 million, a P/E ratio of 52.75 and a beta of 0.72. The stock has a 50 day moving average price of $7.25 and a 200 day moving average price of $9.01.
Analysts Set New Price Targets
Separately, StockNews.com upgraded Vanda Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday.
Institutional Investors Weigh In On Vanda Pharmaceuticals
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals, Inc engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.
- Get a free copy of the StockNews.com research report on Vanda Pharmaceuticals (VNDA)
- Go Where the Money Is. Here’s 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.